Lymphocyte biomarkers for determining the clinical response to cell therapy

ABSTRACT

The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.

BACKGROUND OF THE INVENTION

Adult mesenchymal stem cells (hereinafter also referred to as “MSCs” or“MSC”) have been found in a variety of adult tissues. Having been firstidentified in the bone marrow, MSCs are now accepted to reside in othertissues of mesodermal origin: adipose tissue, placenta, umbilical cord,dental pulp, synovium. Despite ample efforts, no exclusive individualsurface markers have been identified for MSCs. MSCs are definedaccording to the three criteria of the International Society forCellular Therapy: a) Adhesion to plastic: MSCs can be isolated byadhesion to plastic and expanded in vitro in serum containing media withno additional requirements for growth factors or cytokines; b)Expression of a specific combination of surface markers: MSCs arenegative for hematopoetic and endothelial markers such as CD11b, CD14,CD31, CD34 and CD45, and positive for a variety of other markers,including HLA class I, CD73, CD90 and CD105; c) Differentiationpotential: MSCs can be identified in vitro by their ability todifferentiate into mesenchymal-type cells (e.g. trilineagedifferentiation into adipocytes, osteoblasts and chondrocytes). MSCs areat least tripotent at early stages which may be reduced to e.g. bipotentor unipotent cells in the course of in vitro expansion processes.Although sharing these main characteristics, differences between MSCsfrom different sources can be found. Accordingly, the secretome differsbetween cell types, and bone marrow-derived MSCs (BM-MSCs) andadipose-derived MSCs (ASCs) show specific RNA and protein expressionprofiles.

MSCs are considered a promising tool for cell therapy in regenerativemedicine, or for treating other diseases such as ischemic, inflammatoryand immune diseases. Although in situ differentiation was initiallythought to be the basis of their therapeutic properties (i.e. structuraltissue regeneration), it is now believed that their immunomodulatorycapacity and paracrine effects through trophic factors withanti-fibrotic, anti-apoptotic or pro-angiogenic properties are the morelikely mechanisms of their therapeutic effect.

MSCs show immunomodulating properties and regulate the function(proliferation, activation and effector function) of a broad variety ofimmune cells including B lymphocytes, T lymphocytes, NK cells,monocyte-derived dendritic cells and neutrophils. The specific molecularand cellular mechanisms involved in the immunoregulatory activity ofMSCs are still under investigation but rely on both cellcontact-dependent mechanisms (i.e. through Jagged1-Notch1 interaction)and paracrine effects through the release of soluble factors includinghepatocyte growth factor (HGF), prostaglandin-E2 (PGE2), transforminggrowth factor (TGF)-beta 1, indoleamine 2,3-dioxygenase (IDO), nitricoxide (NO), interleukin (IL)-10, IL-6, heme oxygenase-1 (HO-1) orHLA-G5. Furthermore, MSCs may also modulate immune responses through thegeneration of Regulatory T cells (Tregs). These cells are defined by theexpression of CD4, CD25 and the transcription factor Forkhead box p3(Foxp3), and play a central role in protecting from autoimmunity throughtheir immunosupressive capacity.

In addition to this immunomodulatory capacity, an additional potentialadvantage of the clinical use of MSC is that the immunogenicity of MSCis considered to be low. This is due to the fact that the expression ofHLA class I is low, and HLA class II and the classic co-stimulatorymolecules CD40, CD80 and CD86 are not detectable.

One of the first reported (1995) clinical trials involving MSC was thebone marrow derived stromal progenitor cell therapy in the treatment ofpatients having hematologic malignancies. Since then numerous clinicaltrials have been carried out and the first marketing authorizations havebeen granted for MSC therapies. Currently there are several hundredtrials reported involving MSC, for the treatment of indicationsincluding bone disorders (e.g. bone cysts, cleft palate, osteonecritis,spinal fusion), cartilage disorders (e.g. articular cartilage repair andmeniscus repair), hematologic disorders (e.g. anemia, myelodysplasticsyndrome), metabolic diseases (e.g. Type I & II diabetes), liverdiseases (e.g. cirrhosis & failure), cardiovascular diseases (e.g. AMI),gastrointestinal disorders (e.g. IBD and anal fistula), autoimmunedisorders (e.g. rheumatoid arthritis and Crohn's disease), pulmonarydiseases (e.g. COPD and IPF), neurological diseases (e.g. MS, stroke anddisc degeneration), renal diseases (e.g. kidney failure and renaltransplant), urogenital disorders (e.g. urinary incontinence & erectiledisfunction) and opthalogical diseases (e.g. retinitis pigmentosa).

While such on-going investigations illustrate the potential ofmesenchymal stem cells in treating a wide variety of diseases anddisorders the use of biomarkers for the prediction of treatment responsemay potentially aid in the development and use of such therapies.

SUMMARY OF THE INVENTION

The present invention provides novel blood based markers for predictingclinical response to a pharmaceutical composition comprising of stemcells (preferably mesenchymal stem cells), stromal cells, regulatoryT-cells, fibroblasts and combinations thereof (e.g. multipotent stromalor stromal stem cells). In one embodiment said markers are CD3+ cells.In one embodiment said markers are selected from the group comprisingCD4+ lymphocyte level, CD8+ lymphocyte level, lymphocyte HLA-II leveland combinations thereof. Further aspects of the invention providemethods for treating human subjects.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: CD4% and CD8% in patient PBMC in responder and non-respondergroups at baseline

FIG. 2: CD4:CD8 ratio in patient PBMC in responder and non-respondergroups at baseline

FIG. 3: HLA-II expression in patient PBMC at baseline and Day 15 PBMC inresponder and non-responder groups

DETAILED DESCRIPTION OF THE INVENTION Definitions

In order to facilitate the understanding of the present description, themeaning of some terms and expressions in the context of the inventionwill be explained below. Further definitions will be included throughoutthe description as necessary.

The terms “stem cells”, “stromal cells”, “regulatory T-cells” and“fibroblast cells” shall be taken to encompass the progeny thereof,including but not limited to ex-vivo cultured descendants thereof. Itwill be understood that progeny cells may be obtained after any numberof passages from the parental population. However, in certainembodiments, the progeny cells may be obtained after about 2, about 3,about 4, about 5, about 6, about 7, about 8, about 9, or about 10passages from the parental population.

The term “allogeneic” as used herein shall be taken to mean fromdifferent individuals of the same species. Two or more individuals aresaid to be allogeneic to one another when the genes at one or more lociare not identical.

The term “autologous” as used herein shall be taken to mean from thesame individual.

The term “autoimmune disorders” refers to a condition in a subjectcharacterized by cellular, tissue and/or organ injury caused by aninmmunological reaction of the subject to its own cells, tissues and/ororgans. Illustrative, non-limiting examples of autoimmune diseases whichcan be treated with the methods or pharmaceutical compositions of theinvention include alopecia areata, ankylosing spondylitis,antiphospholipid syndrome, autoinmmune Addison's disease, autoimmunediseases of the adrenal gland, autoimmune hemolytic anemia, autoimmunehepatitis, autoimmune oophoritis and orchitis, autoimmunethrombocytopenia, Behcet's disease, bullous pemphigoid, cardiomyopathy,celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome(CFIDS), chronic inflammatory demyelinating polyneuropathy,Churg-Strauss syndrome, cicatrical pemphigoid, CREST syndrome, coldagglutinin disease, discoid lupus, essential mixed cryoglobulinemia,fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease,Guillain-Barre, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis,idiopathic thrombocytopenia purpura (ITP), IgA neuropathy, juvenilearthritis, lichen planus, Meniere's disease, mixed connective tissuedisease, multiple sclerosis, type 1 or immune-mediated diabetesmellitus, myasthenia gravis, pemphigus vulgaris, pernicious anemia,polyarteritis nodosa, polychondritis, polyglandular syndromes,polymyalgia rheumatica, polymyositis and dermatomyositis, primaryagammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriaticarthritis, Raynauld's phenomenon, Reiter's syndrome, sarcoidosis,scleroderma, progressive systemic sclerosis, Sjogren's syndrome, Goodpasture's syndrome, stiff-man syndrome, systemic lupus erythematosus,lupus erythematosus, takayasu arteritis, temporal arteristis/giant cellarteritis, ulcerative colitis, uveitis, vasculitides such as dermatitisherpetiformis vasculitis, vitiligo, Wegener's granulomatosis,Anti-Glomerular Basement Membrane Disease, Antiphospholipid Syndrome,Autoimmune Diseases of the Nervous System, Familial Mediterranean Fever,Lambert-Eaton Myasthenic Syndrome, Sympathetic Ophthalmia,Polyendocrinopathies, Psoriasis, etc.

For the purposes of the invention described herein, “immune disorders”include autoimmune diseases and immunologically mediated diseases suchas but not limited to immune-mediated inflammatory diseases.

The term “inflammatory disease” refers to a condition in a subjectcharacterized by inflammation, e.g. chronic inflammation. Illustrative,non-limiting examples of inflammatory disorders include, but are notlimited to, Celiac Disease, rheumatoid arthritis (RA), InflammatoryBowel Disease (IBD), asthma, encephalitis, chronic obstructive pulmonarydisease (COPD), inflammatory osteolysis, Crohn's disease, ulcerativecolitis, allergic disorders, septic shock, pulmonary fibrosis (e.g.,idiopathic pulmonary fibrosis), inflammatory vacultides (e.g.,polyarteritis nodosa, Wegner's granulomatosis, Takayasu's arteritis,temporal arteritis, and lymphomatoid granulomatosus), post-traumaticvascular angioplasty (e.g. restenosis after angioplasty),undifferentiated spondyloarthropathy, undifferentiated arthropathy,arthritis, inflammatory osteolysis, chronic hepatitis, and chronicinflammation resulting from chronic viral or bacteria infections.

The term “isolated” applied to a cell population refers to a cellpopulation, isolated from the human or animal body, which issubstantially free of one or more cell populations that are associatedwith said cell population in vivo or in vitro. The term “MHC” (majorhistocompatibility complex) refers to a subset of genes that encodescell-surface antigen-presenting proteins. In humans, these genes arereferred to as human leukocyte antigen (HLA) genes. Herein, theabbreviations MHC or HLA are used interchangeably. The term “subject”refers to an animal, preferably a mammal including a non-primate (e.g.,a cow, pig, horse, cat, dog, rat, or mouse) and a primate (e.g., amonkey, or a human). In a preferred embodiment, the subject is a human.

The term “immunomodulatory” refers to the inhibition or reduction of oneor more biological activities of the immune system which includes, butis not limited to, downregulation of immune response and inflammatorystates as well as changes in cytokine profile, cytotoxic activity andantibody production. The term “antigen specific immunomodulatory” refersto the inhibition or reduction of one or more biological activities ofthe immune system associated with a specific antigen or antigens,including both alloantigens and autoantigens. The term“immunomodulatory” shall be taken to comprise “antigen specificimmunomodulatory”.

As used herein, “negative” or “−” as used with respect to cell surfacemarkers shall be taken to mean that mean that, in a cell population,less than 20%, 10%, preferably less than 9%, 8%, 7%, 6%, 59%, 4%, 3%,2%, 1% or none of the cells express said marker. Expression of cellsurface markers may be determined for example by means of flow cytometryfor a specific cell surface marker using conventional methods andapparatus (for example a Beckman Coulter Epics XL FACS system used withcommercially available antibodies and standard protocols known in theart).

As used herein the term “mesenchymal stem cell” (also referred to hereinas “MSC”) shall be taken to mean a stromal cell which is capable ofgiving rise to multiple different types of cell, originally derived fromthe mesenchyme. The term refers to a cell which is capable ofdifferentiating into at least one of an osteoblast, a chondrocyte, anadipocyte, or a myocyte. The term as used herein shall be taken toinclude the progeny of said MSC, for example but not limited tosubcultured descendants thereof.

As used herein, the expression “significant expression” or itsequivalent terms “positive” and “+” when used in regard to a cellsurface marker shall be taken to mean that, in a cell population, morethan 20%, preferably more than, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%,98%, 99% or even all of the cells of the cells express said marker.

Expression of cell surface markers may be determined for example bymeans of flow cytometry for a specific cell surface marker usingconventional methods and apparatus (for example a Beckman Coulter EpicsXL FACS system used with commercially available antibodies and standardprotocols known in the art) that show a signal for a specific cellsurface marker in flow cytometry above the background signal usingconventional methods and apparatus (for example, a Beckman Coulter EpicsXL FACS system used with commercially available antibodies and standardprotocols known in the art). The background signal is defined as thesignal intensity given by a non-specific antibody of the same isotype asthe specific antibody used to detect each surface marker in conventionalFACS analysis. For a marker to be considered positive the specificsignal observed is stronger than 20%, preferably stronger than, 30%,40%, 50%, 60%, 70%, 80%, 90%, 500%, 1000%, 5000%, 10000% or above, thanthe background signal intensity using conventional methods and apparatus(for example a Beckman Coulter Epics XL FACS system used withcommercially available antibodies and standard protocols known in theart).

Furthermore, commercially available and known monoclonal antibodiesagainst said cell-surface markers (e.g., cellular receptors andtransmembrane proteins) can be used to identity relevant cells.

The term “connective tissue” refers to tissue derived from mesenchymeand includes several tissues which are characterized in that their cellsare included within the extracellular matrix. Examples of connectivetissues include but are not limited to, adipose and cartilaginoustissues.

The term “fibroblast” as used herein shall be taken to includefibroblast like synovial cells.

As used herein, the terms “treat”, “treatment” and “treating” when useddirectly in reference to a patient or subject shall be taken to mean theadministration of a pharmaceutical composition to a subject in need ofsaid treatment for the amelioration of one or more symptoms associatedwith a disease or disorder (including, but not limited to, an ischemicdisease, an inflammatory disorder, an autoimmune disease or animmunologically mediated disease including rejection of transplantedorgans and tissues).

The terms “clinical responsiveness”, “clinical response” and “treatmentresponse” shall be taken to mean change of one or more symptomsassociated with a disease or disorder including, but not limited to, anischemic disease, an inflammatory disorder, an autoimmune disease or animmunologically mediated disease including rejection of transplantedorgans and tissues, wherein said change results from the administrationof a pharmaceutical composition to a subject in need of said treatment.

The term “responder” shall be taken to mean an individual, subject orpatient having a disease or disorder (including, but not limited to, anischemic disease, an inflammatory disorder, an autoinmmune disease or animmunologically mediated disease including rejection of transplantedorgans and tissues) wherein a treatment ameliorates or improves one ormore symptoms thereof or otherwise provides therapeutic benefit whereinsaid change results from the administration of a pharmaceuticalcomposition to a subject in need of said treatment.

The term “tissue damage” as used herein shall be taken to include bothsoft tissue injury and hard tissue injury and shall be taken includefistula e.g. anal fistula, rectovaginal fistula etc.

As used herein the terms “treat” and “treating” when used directly inreference to damaged tissues shall be taken to mean the amelioration ofsuch damage by both direct mechanisms such as the regeneration ofdamaged tissues, repair or replacemement of damaged tissues (e.g. byscar tissue) as well as through indirect mechanisms e.g., reducinginflammation thereby enabling tissue formation.

The term “combination therapy” refers to the use of the pharmaceuticalcompositions of the present invention together with other active agentsor treatment modalities, in the manner of the present invention for theamelioration of one or more symptoms associated with a disorderincluding, but not limited to, an inflammatory disorder, an autoimmunedisease or an immunologically mediated disease including rejection oftransplanted organs and tissues. These other agents or treatments mayinclude known drugs and therapies for the treatment of such disorderssuch as but not limited to corticosteroids and non-steroidalanti-inflammatory compounds.

Prognostic Methods.

The present invention provides a method for predicting treatmentresponse to a cellular therapy in patients suffering from tissue damage,ischemic, inflammatory and/or an immune disorder by evaluating ablood-based marker, preferably lymphocytes. In a preferred embodimentsaid “cellular therapy” is the administration of a pharmaceuticalcomposition comprising of stem cells (preferably mesenchymal stemcells), stromal cells, regulatory T-cells, fibroblasts and combinationsthereof (e.g. multipotent stromal or stromal stem cells). In oneembodiment thereof said patient is a human subject having tissue damage,ischemic, inflammatory and/or immune disorders. Accordingly theinvention provides a method for predicting clinical response to theadministration of a pharmaceutical composition comprising of stem cells(preferably mesenchymal stem cells), stromal cells, regulatory T-cells,fibroblasts and combinations thereof (e.g. multipotent stromal orstromal stem cells) in a human subject having tissue damage, ischemic,inflammatory and/or immune disorders. In one embodiment the methodcomprises measuring lymphocytes or CD3+ cell populations in a bloodsample obtained from said human subject and predicting therefromclinical responsiveness to the administration of a pharmaceuticalcomposition comprising of stem cells (preferably mesenchymal stemcells), stromal cells, regulatory T-cells, fibroblasts and combinationsthereof (e.g. multipotent stromal or stromal stem cells).

In one embodiment the method comprises evaluating a marker selected fromthe group comprising CD4+ lymphocyte level, CD8+ lymphocyte level,lymphocyte HLA-II level and combinations thereof in a blood sampleobtained from said human subject and predicting therefrom clinicalresponsiveness to the administration of a pharmaceutical compositioncomprising of stem cells (preferably mesenchymal stem cells), stromalcells, regulatory T-cells, fibroblasts and combinations thereof (e.g.multipotent stromal or stromal stem cells).

In one embodiment the pharmaceutical composition comprises mesenchymalstromal and/or stem cells e.g. multipotent stromal or stromal stemcells. In one embodiment the pharmaceutical composition comprisesadipose derived mesenchymal stromal and/or stem cells.

In one embodiment the CD4+, CD8+ or HLA-II level is measured in humansubject PBMC. In one embodiment the CD4+, CD8+ or HLA-II level ismeasured in human subject lymphocytes. In one embodiment the CD4+, CD8+or HLA-II level is measured in human subject CD3+ lymphocytes.

In one embodiment the CD4+, CD8+ or HLA-II level may be determined as a% of total lymphocyte population, number of cells or ratio.

In an embodiment the marker is CD4+ level. In a further embodiment aCD4+ level equal to or less than a value in the range of 35% to 55%,more preferably 40% to 50% (e.g. less than about 35%; less than about40%; less than about 45%; less than about 50%; less than about 55%) CD4+cells within the T-lymphocyte population is associated with a humansubject predicted to be a responder.

In an embodiment the marker is CD8+ level. In a further embodiment aCD8+ level equal to or greater than a value in the range of 45% to 65%,more preferably 50%-60% (e.g. more than about 45%; more than about 50%;more than about 55%; more than about 60%; more than about 65%) CD8+cells within the T-lymphocyte population is associated with a humansubject predicted to be a responder.

In an embodiment the marker is the CD4+:CD8+ cell ratio. In a furtherembodiment a CD4+:CD8+ cell ratio equal to or lower than 1.5, morepreferably equal to or lower than a value in the range of 1.2 to 0.5,most preferably equal to or lower than 1 (e.g. less than about 1.2; lessthan about 1.1; less than about 1; less than about 0.9; less than about0.8; less than about 0.7; less than about 0.6) is associated with ahuman subject predicted to be a responder.

In an embodiment the marker is HLA-II level. In a further embodiment areduction in lymphocyte HLA-II level after contact thereof withallogeneic mesenchymal stem cells is associated with a human subjectpredicted to be a responder.

The HLA-II level is considered reduced when its levels decrease withrespect to a reference value by at least 5%, by at least 10%, by atleast 15%, by at least 20%, by at least 25%, by at least 30%, by atleast 35%, by at least 40%, by at least 45%, by at least 50%, by atleast 55%, by at least 60%, by at least 65%, by at least 70%, by atleast 75%, by at least 80%, by at least 85%, by at least 90%, by atleast 95%, by at least 100% (i.e., absent).

The reference value used to determine whether the HLA-II level isreduced is, for instance, the HLA-II level in lymphocytes not stimulatedwith allogeneic stem cells. Moreover, the HLA-II level in non-stimulatedlymphocytes can be determined in a sample from the same patient which isgoing to be treated. Alternatively it is also possible to obtain thereference value from lymphocytes from a different individual or fromlymphocytes pooled from the blood of a population of two or moreindividuals. The population, for example, can comprise 3, 4, 5, 10, 15,20, 30, 40, 50 or more individuals.

In one embodiment the CD4+, CD8+ or HLA-II level is measured prior toadministration of the pharmaceutical composition. In a furtherembodiment the CD4+, CD8+ or HLA-II level is measured subsequent toadministration of the pharmaceutical composition. In one embodiment theCD4+, CD8+ or HLA-II level is measured at least 1, 5, 10, 15 or 20 daysafter administration of the pharmaceutical composition. In oneembodiment the CD4+, CD8+ or HLA-II level is measured both prior to andsubsequent to administration of the pharmaceutical composition. Inanother embodiment wherein the pharmaceutical composition isadministered a plurality of times to the patient the CD4+, CD8+ orHLA-II level is measured prior to and/or subsequent to administration ofthe pharmaceutical composition.

Treatment Methods.

The present invention provides a method for treating a human subjecthaving tissue damage, ischemic, inflammatory and/or immune disorderswith a pharmaceutical composition comprising of stem cells (preferablymesenchymal stem cells), stromal cells, regulatory T-cells, fibroblastsand combinations thereof (e.g. multipotent stromal or stromal stemcells).

In one embodiment the method comprises i) determining whether thepatient is a responder or a non-responder to said pharmaceuticalcomposition by measuring CD3+ cell populations in a blood sampleobtained from said human subject and ii) administering saidpharmaceutical composition only if the human subject is determined to bea responder.

In one embodiment the method comprises i) determining whether thepatient is a responder or a non-responder to said pharmaceuticalcomposition by evaluating a marker selected from the group comprisingCD4+ lymphocyte level, CD8+ lymphocyte level, lymphocyte HLA-II leveland combinations thereof in a blood sample obtained from said humansubject and ii) administering said pharmaceutical composition only ifthe human subject is determined to be a responder.

In one embodiment the patient has not previously been treated with apharmaceutical composition comprising of stem cells (preferablymesenchymal stem cells), stromal cells, regulatory T-cells, fibroblastsand combinations thereof (e.g. multipotent stromal or stromal stemcells). In an alternative embodiment the patient is administered apharmaceutical composition comprising of stem cells (preferablymesenchymal stem cells), stromal cells, regulatory T-cells, fibroblastsand combinations (e.g. multipotent stromal or stromal stem cells)thereof prior to i) and administration of said pharmaceuticalcomposition is only continued or a subsequent dose thereof is onlyadminstered if the human subject is identified as a responder.

In one embodiment the pharmaceutical composition comprises mesenchymalstromal and/or stem cells e.g. multipotent stromal or stromal stemcells. In one embodiment the pharmaceutical composition comprisesadipose derived mesenchymal stromal and/or stem cells. In a furtherembodiment said mesenchymal stromal and/or stem cells are expanded priorto i).

In one embodiment the CD4+, CD8+ or HLA-II level is measured in patientPBMC. In one embodiment the CD4+, CD8+ or HLA-II level is measured inpatient lymphocytes. In one embodiment the CD4+, CD8+ or HLA-II level ismeasured in human subject CD3+ lymphocytes.

In one embodiment the CD4+, CD8+ or HLA-II level may be determined as a% of total lymphocyte population, number of cells or ratio.

In an embodiment the marker is CD4+ level. In a further embodiment aCD4+ level equal to or less than a value in the range of 35% to 55%,more preferably 40% to 50% (e.g. less than about 35%; less than about40%; less than about 45%; less than about 50%; less than about 55%) CD4+cells within the T-lymphocyte population is associated with a humansubject classified as a responder.

In an embodiment the marker is CD8+ level. In a further embodiment aCD8+ level equal to or greater than a value in the range of 45% to 65%,more preferably 50%-60% (e.g. more than about 45%; more than about 50%;more than about 55%; more than about 60%; more than about 65%) CD8+cells within the T-lymphocyte population is associated with a humansubject classified as a responder.

In an embodiment the marker is the CD4+:CD8+ cell ratio. In a furtherembodiment a CD4+:CD8+ cell ratio equal to or lower than 1.5, morepreferably equal to or lower than a value in the range of 1.2 to 0.5,most preferably equal to or lower than 1 (e.g. less than about 1.2; lessthan about 1.1; less than about 1; less than about 0.9; less than about0.8; less than about 0.7; less than about 0.6) is associated with ahuman subject as a responder.

In an embodiment the marker is HLA-II level. In a further embodiment areduction in lymphocyte HLA-II level after contact thereof withallogeneic mesenchymal stem cells is associated with a human subjectclassified as a responder.

The HLA-II level is considered reduced when its levels decrease withrespect to a reference value by at least 5%, by at least 10%, by atleast 15%, by at least 20%, by at least 25%, by at least 30%, by atleast 35%, by at least 40%, by at least 45%, by at least 50%, by atleast 55%, by at least 60%, by at least 65%, by at least 70%, by atleast 75%, by at least 80%, by at least 85%, by at least 90%, by atleast 95%, by at least 100% (i.e., absent).

The reference value used to determine whether the HLA-II level isreduced is, for instance, the HLA-II level in lymphocytes not stimulatedwith allogeneic stem cells. Moreover, the HLA-II level in non-stimulatedlymphocytes can be determined in a sample from the same patient which isgoing to be treated. Alternatively it is also possible to obtain thereference value from lymphocytes from a different individual or fromlymphocytes pooled from the blood of a population of two or moreindividuals. The population, for example, can comprise 3, 4, 5, 10, 15,20, 30, 40, 50 or more individuals.

In one embodiment the CD4+, CD8+ or HLA-II level is measured prior toadministration of the pharmaceutical composition. In one embodiment theCD4+, CD8+ or HLA-II level is measured at least 1, 5, 10, 15 or 20 daysafter administration of the pharmaceutical composition.

Medical Uses.

In one aspect the present invention provides a pharmaceuticalcomposition comprising of stem cells (preferably mesenchymal stemcells), stromal cells, regulatory T-cells, fibroblasts and combinationsthereof (e.g. multipotent stromal or stromal stem cells) for thetreatment, modulation, prophylaxis, and/or amelioration of one or moresymptoms associated with tissue damage, ischemic, inflammatory and/orimmune disorders in a human subject.

In one embodiment the invention provides a pharmaceutical compositioncomprising of stem cells (preferably mesenchymal stem cells), stromalcells, regulatory T-cells, fibroblasts and combinations thereof (e.g.multipotent stromal or stromal stem cells) for treatment, modulation,prophylaxis, and/or amelioration of one or more symptoms associated withtissue damage, ischemic, inflammatory and/or immune disorders in a humansubject wherein said human subject has a CD4+ level equal to or lessthan a value in the range of 35% to 55%, more preferably 40% to 50%(e.g. less than about 35%; less than about 40%; less than about 45%;less than about 50%; less than about 55%) of T-lymphocytes.

In a further embodiment the invention provides the use of stem cells(preferably mesenchymal stem cells), stromal cells, regulatory T-cells,fibroblasts and combinations thereof (e.g. multipotent stromal orstromal stem cells in the manufacture of a pharmaceutical compositionfor treatment, modulation, prophylaxis, and/or amelioration of one ormore symptoms associated with tissue damage, ischemic, inflammatoryand/or immune disorders in a human subject wherein said human subjecthas a CD4+ level equal to or less than a value in the range of 35% to55%, more preferably 40% to 50% (e.g. less than about 35%; less thanabout 40%; less than about 45%; less than about 50%; less than about55%) of T-lymphocytes.

In one embodiment the invention provides a pharmaceutical compositioncomprising of stem cells (preferably mesenchymal stem cells), stromalcells, regulatory T-cells, fibroblasts and combinations thereof (e.g.multipotent stromal or stromal stem cells) for treatment, modulation,prophylaxis, and/or amelioration of one or more symptoms associated withtissue damage, ischemic, inflammatory and/or immune disorders in a humansubject wherein said human subject has a CD8+ level equal to or greaterthan a value in the range of 45% to 65%, more preferably 50%-60% (e.g.more than about 45%; more than about 50%; more than about 55%; more thanabout 60%; more than about 65%) of T-lymphocytes.

In a further embodiment the invention provides the use of stem cells(preferably mesenchymal stem cells), stromal cells, regulatory T-cells,fibroblasts and combinations thereof (e.g. multipotent stromal orstromal stem cells in the manufacture of a pharmaceutical compositionfor treatment, modulation, prophylaxis, and/or amelioration of one ormore symptoms associated with tissue damage, ischemic, inflammatoryand/or immune disorders in a human subject wherein said human subjecthas a CD8+ level equal to or greater than a value in the range of 45% to65%, more preferably 50%-60% (e.g. more than about 45%; more than about50%; more than about 55%; more than about 60%; more than about 65%) ofT-lymphocytes.

In one embodiment the invention provides a pharmaceutical compositioncomprising of stem cells (preferably mesenchymal stem cells), stromalcells, regulatory T-cells, fibroblasts and combinations thereof (e.g.multipotent stromal or stromal stem cells) for treatment, modulation,prophylaxis, and/or amelioration of one or more symptoms associated withtissue damage, ischemic, inflammatory and/or immune disorders in a humansubject wherein said human subject has a CD4+:CD8+ cell ratio equal toor lower than 1.5, more preferably equal to or lower than a value in therange of 1.2 to 0.5, most preferably equal to or lower than 1 (e.g. lessthan about 1.2; less than about 1.1; less than about 1; less than about0.9; less than about 0.8; less than about 0.7; less than about 0.6).

In a further embodiment the invention provides the use of stem cells(preferably mesenchymal stem cells), stromal cells, regulatory T-cells,fibroblasts and combinations thereof (e.g. multipotent stromal orstromal stem cells in the manufacture of a pharmaceutical compositionfor treatment, modulation, prophylaxis, and/or amelioration of one ormore symptoms associated with tissue damage, ischemic, inflammatoryand/or immune disorders in a human subject wherein said human subjecthas a CD4+:CD8+ cell ratio equal to or lower than 1.5, more preferablyequal to or lower than a value in the range of 1.2 to 0.5, mostpreferably equal to or lower than 1 (e.g. less than about 1.2; less thanabout 1.1; less than about 1; less than about 0.9; less than about 0.8;less than about 0.7; less than about 0.6).

In a further embodiment the invention provides the use of stem cells(preferably mesenchymal stem cells), stromal cells, regulatory T-cells,fibroblasts and combinations thereof (e.g. multipotent stromal orstromal stem cells in the manufacture of a pharmaceutical compositionfor treatment, modulation, prophylaxis, and/or amelioration of one ormore symptoms associated with tissue damage, ischemic, inflammatoryand/or immune disorders in a human subject wherein said human subjecthas a reduction in lymphocyte HLA-II level after contact thereof withallogeneic mesenchymal stem cells. In a preferred embodiment, the HLA-IIlevel is considered reduced when it shows a decrease with respect to areference value by at least 5%, by at least 10%, by at least 15%, by atleast 20%, by at least 25%, by at least 30%, by at least 35%, by atleast 40%, by at least 45%, by at least 50%, by at least 55%, by atleast 60%, by at least 65%, by at least 70%, by at least 75%, by atleast 80%, by at least 85%, by at least 90%, by at least 95%, by atleast 100% (i.e., absent).

The reference value used to determine whether the HLA-II level isreduced is, for instance, the HLA-II level in lymphocytes not stimulatedwith allogeneic stem cells. Moreover, the HLA-II level in non-stimulatedlymphocytes can be determined in a sample from the same patient which isgoing to be treated. Alternatively it is also possible to obtain thereference value from lymphocytes from a different individual or fromlymphocytes pooled from the blood of a population of two or moreindividuals. The population, for example, can comprise 3, 4, 5, 10, 15,20, 30, 40, 50 or more individuals.

In one embodiment the invention provides a pharmaceutical compositioncomprising of stem cells (preferably mesenchymal stem cells), stromalcells, regulatory T-cells, fibroblasts and combinations thereof (e.g.multipotent stromal or stromal stem cells) for treatment, modulation,prophylaxis, and/or amelioration of one or more symptoms associated withtissue damage, ischemic, inflammatory and/or immune disorders in a humansubject wherein said human subject has a reduction in lymphocyte HLA-IIlevel after contact thereof with allogeneic mesenchymal stem cells.

In a further embodiment the invention provides the use of stem cells(preferably mesenchymal stem cells), stromal cells, regulatory T-cells,fibroblasts and combinations thereof (e.g. multipotent stromal orstromal stem cells in the manufacture of a pharmaceutical compositionfor treatment, modulation, prophylaxis, and/or amelioration of one ormore symptoms associated with tissue damage, ischemic, inflammatoryand/or immune disorders in a human subject wherein said human subjecthas a reduction in lymphocyte HLA-II level after contact thereof withallogeneic mesenchymal stem cells.

Immunophenotyping.

Methods for the measurement of HLA-II+, CD4+ and CD8+ lymphocytepopulations are well known in the art. The gold standard method forquantification of said cells is by flow cytometry. Staining panels arecommercially available for the fluorescence tag detection of saidlymphocyte cell populations. Typically % of each subpopulation isdetermined by staining for the specific marker within the CD3population. Conversion of % to cell counts can be carried out by using avolumetric approach, either by analyzing a fixed volume of sample orrecording the volume of any given sample. Alternatively beads-basedsystems allow the conversion of % to absolute cell counts by usingfluorescent beads to spike samples and thus measure sample volume. Thevolumetric or beads-based approaches are referred to as single platformapproaches, and are commercially available e.g. TruCount (BecktonDickinson) and FlowCould (Beckton Coulter). Additionally dedicatedplatfo-ms for CD4+ analysis are also available e.g. FACScount (BecktonDickinson). An alternative methodology for lymphocyte quantification isthe use of haematology analyser for measurement of total lymphocytecount as a reference for the FACS measurement. Often referred to as the“dual platform” approach, approaches such as “pan-leucogating” are knownin the art for quantification of lymphocyte sub-populations using thecombined platform approach. As an alternative to flow cytometry manualmethods using microscopy in combination with haemocytometers are known.Commercially available kits utilize immunomagnetic beads for theisolation of cell subpopulations that may be subsequently counted underthe microscope.

Pharmaceutical Compositions.

In one embodiment the pharmaceutical composition of the inventioncomprises a prophylactically or therapeutically effective amount of stemcells (preferably mesenchymal stem cells), stromal cells, regulatoryT-cells, fibroblasts and combinations thereof (e.g. multipotent stromalor stromal stem cells) and a pharmaceutical carrier. In one embodimentthe pharmaceutical composition comprises mesenchymal stem or stromalcells, more preferably adipose-derived mesenchymal stem or stromalcells.

In one embodiment a pharmaceutical composition will comprise the numberof cells required for one dose; suitable cell numbers per dose are forexample between about 100 and about 100 million cells; between about1000 and about 10 million cells; between about 10,000 and about 1million cells; between about 100 and about 1000 cells; between about1000 and about 10,000 cells; between about 10,000-100,000 cells; betweenabout 100,000-1 million cells; between about 1 million-10 million cells;between about 10 million-100 million cells.

Suitable pharmaceutical carriers are known in the art and are preferablythose approved by a regulatory agency of the US Federal or a stategovernment or listed in the U S Pharmacopeia, or European Pharmacopeia,or other generally recognized pharmacopeia for use in animals, and moreparticularly in humans. The term “carrier” refers to a diluent,adjuvant, excipient, vehicle or support with which the therapeutic agentis administered. The composition, if desired, can also contain minoramounts of pH buffering agents. Examples of suitable pharmaceuticalcarriers are described in “Remington's Pharmaceutical Sciences” by E WMartin. Such compositions will contain a prophylactically ortherapeutically effective amount of a prophylactic or therapeutic agentpreferably in purified form, together with a suitable amount of carrierso as to provide the form for proper administration to the subject. Theformulation should suit the mode of administration. In a preferredembodiment, the pharmaceutical compositions are sterile and in suitableform for administration to a subject, preferably an animal subject, morepreferably a mammalian subject, and most preferably a human subject.

The pharmaceutical composition of the invention may be in a variety offorms. These include, for example, semi-solid, and liquid dosage forms,such as lyophilized preparations, liquid solutions or suspensions,injectable and infusible solutions, etc. The pharmaceutical compositionis preferably injectable.

The pharmaceutical compositions of the invention may also be combinedwith other treatment modalities, e.g., corticosteroids, non-steroidalanti-inflammatory compounds, or other agents useful in treatinginflammation. The combined use of the agents of the present inventionwith these other therapies or treatment modalities may be concurrent, orgiven sequentially, that is, the two treatments may be divided up suchthat said therapies or pharmaceutical compositions of the invention maybe given prior to or after the other therapy or treatment modality. Theattending physician may decide on the appropriate sequence ofadministering the immunomodulatory cells, or a pharmaceuticalcomposition comprising same, in combination with other agents, therapiesor treatment modalities.

It is preferred that the pharmaceutical compositions according to thepresent invention comprises stem cells, stromal cells regulatory T-cellsand/or fibroblast cells. It is particularly preferred that said stem orstromal cells are mesenchymal stem cells (hereinafter also referred toas MSC), most preferably adipose derived stem cells (hereinafter alsoreferred to as ASC), which are multipotent stromal cells that originatefrom adipose tissue, preferably from human adipose tissue (hASCs).

The MSC used in the method of the present invention are preferablyderived from connective tissue, most preferably stromal tissue. In apreferred embodiment said MSC are derived from adipose tissue and in afurther preferred embodiment from the stromal fraction of the adiposetissue. In an alternative embodiment, said MSC are obtained fromchondrocytes of the hyaline cartilage. In a further embodiment, said MSCare obtained from skin. In another embodiment, said MSC are obtainedfrom bone marrow.

The MSC can be obtained from any suitable source of connective tissuefrom any suitable animal, most preferably humans. It is preferred thatsaid cells are obtained from non-pathological mammalian sources,preferably post-natal (e.g., rodent or primate) sources. In a preferredembodiment, the MSC are obtained from a source of connective tissue,such as, but not limited to, the stromal fraction of adipose tissue,hyaline cartilage, bone marrow or skin. Most preferably the MSC of themethods of the present invention are obtained from non-pathological,post-natal, human stromal adipose tissue.

The fibroblasts used in the present invention are mesenchyme derivedconnective tissue that are associated with the synthesis and maintenanceof extra cellular matrix and shall be taken to include fibroblast likesynovial cells. The fibroblasts can be obtained from any suitableanimal, most preferably human.

The regulatory T-cells (alternatively known as suppressor T-cells) asused in the present invention may be derived from any suitable source,such as blood or spleen. The regulatory T-cells may be naturallyoccurring CD4+Foxp3+ cells, or they may be ex-vivo isolated and/orexpanded regulatory T-cells. Methods for the ex-vivo expansion ofregulatory T-ceils are known in the art and include the isolation fromwhole blood (e.g., as part of the PBMC fraction) followed by expansionusing e.g., mesenchymal stem cells or Rapamycin.

With respect to the intended recipient of the pharmaceuticalcompositions as administered according to the present invention, theMSC, regulatory T-cells and/or fibroblast cells may be of eitherallogeneic (donor) or autologous (subject) origin. In a preferredembodiment of the method said MSC, regulatory T-cells and/or fibroblastcells are of allogeneic origin.

The MSC used in the method of the present invention are preferablycharacterized in that (i) they do not express markers specific forantigen presenting cells, (ii) they do not express IDO (Indoleamine2,3-Dioxygenase) constitutively, (iii) they express IDO upon stimulationwith IFN-gamma, and in the case of MSC (iv) they present the capacity tobe differentiated into at least two cell lineages.

MSC are multipotent stem cells and have the capacity to proliferate andbe differentiated into at least two, more preferably three, four, five,six, seven or more cell lineages. Illustrative, non-limiting examples ofcell lineages into which said MSC can be differentiated includeosteocytes, adipocytes, chondrocytes, tenocytes, myocytes,cardiomyocytes, hematopoietic-supporting stromal cells, endothelialcells, neurons, astrocytes, and hepatocytes. MSC can proliferate and beinduced differentiate into cells of other lineages by conventionalmethods. Methods of identifying and subsequently isolatingdifferentiated cells from their undifferentiated counterparts can bealso carried out by methods well known in the art.

Preferably the MSC are ex-vivo cultured cells, methods for the expansionof MSC populations are known in the art. Subsequent to isolation MSC canbe maintained and allowed to proliferate ex vivo in a cell culturemedium. Such medium may be composed of, for example, Dulbecco's ModifiedEagle's Medium (DMEM), with antibiotics (for example, 100 units/mlPenicillin and 100 μg/ml Streptomycin) or without antibiotics, and 2 mMglutamine, and supplemented with 2%-20% fetal bovine serum (FBS). It iswithin the skill of one in the art to modify or modulate concentrationsof media and/or media supplements as necessary for the cells used. Seraoften contain cellular and non-cellular factors and components that arenecessary for viability and expansion. Examples of sera include fetalbovine serum (FBS), bovine serum (BS), calf serum (CS), fetal calf serum(FCS), newborn calf serum (NCS), goat serum (GS), horse serum (HS),porcine serum, sheep serum, rabbit serum, rat serum (RS), etc. It isalso within the scope of the invention that if said MSC are of humanorigin, the cell culture medium is supplemented with a human serum,preferably of autologous origin. It is understood that sera can beheat-inactivated at 55-65° C. if deemed necessary to inactivatecomponents of the complement cascade. Modulation of serum concentrationsand/or withdrawal of serum from the culture medium can also be used topromote survival of one or more desired cell types. Preferably, said MSCwill benefit from FBS concentrations of about 2% to about 25%. Inanother embodiment, the MSC can be expanded in a cell culture medium ofdefinite composition, in which the serum is replaced by a combination ofserum albumin, serum transferrin, selenium, and recombinant proteinsincluding but not limited to insulin, platelet-derived growth factor(PDGF), and basic fibroblast growth factor (bFGF) as known in the art.

Many cell culture media already contain amino acids, however somerequire supplementation prior to culturing of cells. Such amino acidsinclude, but are not limited to, L-alanine, L-arginine, L-aspartic acid,L-asparagine, L cysteine, L-cystine, L-glutamic acid, L-glutamine,L-glycine, and the like.

Antimicrobial agents are also typically used in cell culture to mitigatebacterial, mycoplasmal, and fungal contamination. Typically, antibioticsor anti-mycotic compounds used are mixtures of penicillin/streptomycin,but can also include, but are not limited to amphotericin (Fungizone®),ampicillin, gentamicin, bleomycin, hygromacin, kanamycin, mitomycin,etc.

Hormones can also be advantageously used in cell culture and include,but are not limited to, D-aldosterone, diethylstilbestrol (DES),dexamethasone, b-estradiol, hydrocortisone, insulin, prolactin,progesterone, somatostatin/human growth hormone (HGH), etc.

In one embodiment the stem cells (preferably mesenchymal stem cells),stromal cells, regulatory T-cells, fibroblasts and combinations thereof(e.g. multipotent stromal or stromal stem cells) may have be autologous,allogeneic or xenogenic. It is particularly preferred that said stemcells (preferably mesenchymal stem cells), stromal cells, regulatoryT-cells, fibroblasts and combinations thereof (e.g. multipotent stromalor stromal stem cells) are allogeneic to the patient or subject to whichthey are administered or intended for administration.

Expanded Cells.

In one embodiment the stem cells (preferably mesenchymal stem cells),stromal cells, regulatory T-cells, fibroblasts and combinations thereof(e.g. multipotent stromal or stromal stem cells) may have been expandedprior to use in the methods and compositions of the present invention.

In certain embodiments, the cells may be cultured for at least about 15days, at least about 20 days, at least about 25 days, or at least about30 days. The expansion of cells in culture may improve the homogeneityof the cell phenotype in the cell population, accordingly in a preferredembodiment said cells are cultured until substantially homogenous.

In certain embodiments, the cells are expanded in culture for at leastthree culture passages or “passaged at least three times”. In otherembodiments, the cells are passaged at least four times, at least fivetimes, at least six times, at least seven times, at least eight times,at least nine times, or at least ten times. It is appreciated thatmultilineage differentiation potential of the cells may decrease duringexpansion, e.g. with successive passaging of the cells; such progenycells are nonetheless within the scope of the embodiments of the presentinvention. Methods for cell expansion are known in the art and maycomprise the use of commercially available 2D or 3D bioreactors.

Cryopreserved Cells.

In one embodiment the stem cells (preferably mesenchymal stem cells),stromal cells, regulatory T-cells, fibroblasts and combinations thereof(e.g. multipotent stromal or stromal stem cells) may have beencryopreserved and thawed prior to use in the methods and compositions ofthe present invention.

Methods for the cryopreservation of stem cells are known in the art andmay include the use of cryopreservation buffers or medium. Such buffersare known in the art and are commercially available.

Genetically Engineered Cells

In another embodiment the MSC, regulatory T-cells and/or fibroblastcells may be genetically engineered cells (e.g. transduced ortransfected with an exogenous nucleic acid), or derived therefrom.

For example said cells may be genetically engineered to constitutivelyexpress indoleamine 2,3-dioxygenase (IDO), e.g., by transfection with anappropriate nucleic acid construct encoding said enzyme and optionally asuitable promoter sequence. Genetic engineering of cells is known in theart and may be carried out by a person skilled in the art.

Irradiated Cells.

In yet another embodiment the MSC, regulatory T-cells and/or fibroblastcells may have been irradiated prior to their use in the method of thepresent invention. Irradiation of cells reduces their proliferativecapabilities and survival times.

The irradiation may be carried out using a suitable controlled source ofionizing radiation, such a gamma irradiator device. The irradiationconditions must be experimentally adjusted by a person skilled in theart to determine the required exposure time to impart a radiation dosethat causes the long term growth arrest of the MSC, regulatory T-cellsand/or fibroblast cells. In one embodiment said radiation dose is withina range selected from the group consisting of 1-100 Gy; 5-85 Gy, 10-70Gy, 12-60 Gy, however, it is particularly preferred that said radiationdose is within the range of 15-45 Gy, typically 20-30 Gy or 22-28 Gy.

CD26 Antagonist Treated Cells.

In still another embodiment the MSC, regulatory T-cells and/orfibroblast cells may be treated with a CD26 antagonist or inhibitorprior to use in the method of the present invention. CD26 antagonistsand inhibitors are known in the art and include but are not limited toAminomethylpyridine; P32/98; NVP DPP728; PSN9301; Isoleucinethiazolidide; Denagliptin; Sitagliptin; Vildagliptin; Saxagliptin;Alogliptin; Diprotin A, and such treatment may be carried out by aperson skilled in the art.

IFN-Gamma Stimulated Cells.

In another embodiment the MSC, regulatory T-cells and/or fibroblastcells may be stimulated with interferon gamma prior to use in the methodof the present invention. IFN-gamma treatment of MSC for the stimulationthereof is known in the art (e.g. Krampera et al, Stem Cells. 2006February; 24(2):386-98) and may be carried out by a person skilled inthe art.

Antigen Stimulated Cells

In still another embodiment the MSC, regulatory T-cells and/orfibroblast cells may be stimulated with antigens prior to use in themethod of the present invention. Antigen treatment of MSC for thestimulation thereof is known in the art and may be carried out by aperson skilled in the art.

Mitomycin C Treated Msc.

In yet another embodiment the MSC, regulatory T-cells and/or fibroblastcells may be treated with Mitomycin C prior to use in the method of thepresent invention. Mitomycin C treatment of MSC is known in the art andmay be carried out by a person skilled in the art.

Furthermore, it desired, the MSC, regulatory T-cells and/or fibroblastcells can be subjected to a combination of two or three of thetreatments selected from the group consisting of irradiation, IFN-gammastimulation and Mitomycin C treatment prior to use in the method of thepresent invention.

The maintenance conditions of said MSC can also contain cellular factorsthat allow cells to remain in an undifferentiated form. It is apparentto those skilled in the art that prior to differentiation, supplementsthat inhibit cell differentiation must be removed from the culturemedium. It is also apparent that not all cells will require thesefactors. In fact, these factors may elicit unwanted effects, dependingon the cell type.

Various embodiments of the invention will be illustrated by thefollowing examples, which illustrate but do not limit the inventiondescribed herein.

Example 1

Evaluation of Lymphocyte biomarkers in USC Therapy Responders andNon-Responders.

Stem cell therapies have significant potential for use in the treatmentof disorders characterized by tissue damage and inflammation. In orderto identify blood-based markers having utility in determining patientprognosis for such therapies anal fistula in Crohn's patients is anideal model disorder as it is characterized by tissue damage in apatient having an inflammatory disease. Lymphocyte analysis in patientblood samples was carried out both before and after treatment withallogeneic expanded adipose-derived cells (eASC).

Materials & Methods Patient Population

The patient population consisted of 24 Crohn's patients having complexperianal fistula treated in a multicenter Phase I/II a clinical trial(clinicaltrials.gov identifier NCT01372969). Patients were treated withan intralesional administration of 20 million eASC. Fistula healing wasdetermined 12 weeks post-treatment, and in case of incomplete healing asecond dose of 40 million eASC was administered. Whole blood wascollected from patients at two time points during the trial, baselineand 15 days.

An MRI was performed at baseline to assess collections >2 cm associatedwith the fistula tract. Subjects were followed for 24 weeks in total andhealing was assessed at weeks 12 and 24 by means of radiological andclinical assessment.

Fistula closure at 12 weeks was used to define patients as responders(n=9), all other patients were defined as non-responders (n=15). Fistulaclosure was defined as the absence of suppuration of the fistula throughthe external orifice, both spontaneously and upon application ofpressure, with complete reepithelization of the external orifice duringclinical evaluation and absence of collections >2 cm, in three axis,directly related to the fistula tract treated, as measured by MRI.Fistulas were evaluated at two consecutive visits, i.e., weeks 10; 12and 22; 24 to avoid misinterpretation and guide treatment decisions.Fistula evaluation was carried out by both the attending physician andan independent clinician. Table 1 provides an overview of the responsestatus of each individual subject and the analysis carried out on theirblood samples.

PEMC Isolation

Blood samples were collected from the patients at baseline and at 15days. Peripheral blood mononuclear cells (PBMC) were isolated from theblood samples using Ficoll-paque Plus (GE Healthcare Biosciences AB,Uppsala, Sweden) following the supplier's protocol. Briefly, bloodsamples were diluted with balanced salt solution and Ficoll was added tocreate a density gradient. After centrifugation, the interfacecontaining mononuclear cells was collected. Purity was verified by flowcytometry.

Mesenchymal Stem Cells

The allogeneic eASC medicinal product consisted of a cellular suspensionof living adult stem cells of mesenchymal origin extracted from thesubdermal adipose tissue of healthy donors. Subdermal adipose tissue wasliposuctioned from the healthy donor and transported to themanufacturing facility. The donation, procurement, and testing werecarried out according to the requirements of Directive 2004/23/EC andtherefore under Directives 2006/17/EC and 2006/83/EC. ASCs were isolatedby digesting the adipose tissue with 0.075% collagenase (Type I,Invitrogen, Carlsbad, Calif.), followed by centrifugation. The cellpellet obtained was resuspended and lysed in erythrocyte lysis solution(10% fetal bovine serum (FBS), treated with 160 mM NH₄Cl) andcentrifuged. The stromal vascular fraction, resulting from the cellpellet was resuspended in culture medium (Dulbecco's modified Eaglemedium; DMEM) with 10% FBS) and placed in cell culture containers inculture medium and antibiotics, and incubated at 37° C. and 5% CO2 andin a humidified atmosphere. At 24-48 h post-plating, the culture mediumwas removed to eliminate the non-attached cell fraction. ASCs adhered tothe plastic culture plates that were expanded under in vitro conditions.Every 3-4 days, the culture medium was changed after reaching 90-95%confluence and the cells were detached with trypsin/EDTA, collected,centrifuged, and expanded without antibiotics to the requiredduplication. They were then harvested and cryopreserved until use.Before the appointed administration date, sufficient cryopreserved vialswere thawed to provide the required dose for administration. ASCs wererecovered from their cryopreserved state by plating and culturing (toconfirm viability). On the day when the vials were filled and packaged,the cultures were washed with phosphate buffer solution, andtrypsin/EDTA. The eASC were immediately resuspended in the selectedexcipients (Dulbecco modification Eagle medium and human albumin serum)to formulate the drug product.

Flow Cytometry.

Antibodies against CD3, CD4, CD8, CD25, FOXP3, HLA-II, (BD Bioscience)labelled with different fluorochromes were used. Isotype controls werefrom BD Bioscience. Cells were harvested and stained with theappropriate surface monoclonal antibodies following manufacturerinstructions. After washing, cells were fixed and 10×10³ events wereacquired using a FACSCanto (BD Bioscience). FACS Diva software was usedfor acquisition and analysis.

Immnophenotyping of Circulating T Cells

The cellular repertoire in peripheral blood from the patients wasstudied at baseline and at 15 days. The peripheral blood mononuclearfraction was selected for the phenotypic analysis of the T (defined byCD3+), helper T cells (Defined by CD3+CD4+), and cytotoxic T cells(defined by CD3+CD8+).

Lymphocyte HLA-II Expression

Expression levels of HLA II upon in vitro co-culture of the patient PBMCsamples with the allogeneic eASC of the medicinal product weredetermined as an indicator of in-vivo immune recognition of the donoreASC. Briefly, eASC were seeded in a 96-well plate (3×10³) and culturedfor 24 hours, alone or in the presence of PBMCS (2×10⁵) from each of thepatients in the trial. After culture cells were harvested and FACSanalysis was performed. Monoclonal antibodies against CD3 and HLA II,were used to measure HLA II expression on T cells after the in-vitroincubation with or without eASCs (control).

Statistics

Paired Student's t-test was used to analyze statistic difference. Thep-values less than 0.05 were considered as significant.

Results T Cell Immunophenotype

Circulating cell repertoire of the participants of the study wasanalyzed by flow cytometry. Percentage of distribution of T cells (CD3+population in the lymphocyte region), helper T cells, cytotoxic T cellsand regulatory T cells was studied in isolated PBMCs in the groups ofresponder and non responder patients in the samples collected beforebeing treated with eASCs.

Variations in the T cell compartment were observed between the responderand non-responder groups. As shown in FIG. 1 the responder grouppresented lower levels of CD4 T (45.2±5% of the CD3+ cell population)cells and higher levels of CD8 (54.8±5% of the CD3+ cell population) Tcells than the non responder population. The non-responder grouppresented a relatively normal distribution of CD4 and CD8 T cells(34.99±7% of CD8 and 65.01±7% of CD4 of the total CD3+ cell population).Accordingly cut-off values in the range of 45% to 65%, more preferably50%-60% CD8+ lymphocytes and 35% to 55%, more preferably 40% to 50% CD4+lymphocytes is suitable for discriminating between the responder andnon-responder populations.

As an alternative means of expressing these values the CD4:CD8 ratio wascalculated and is provided in FIG. 2. This data showed that thenon-responder population had a mean CD4:CD8 ratio over 1.5, however theresponder population, due to the increase of the cytotoxic cellcompartment and the decreased helper population have a mean ratio below1.5 indicating that this group of patients had a more immune activatedprofile.

Lymphocyte HILA-II Expression

Expression levels of HLA II upon in vitro co-culture of the volunteerPBMC samples (both pre- and post-eASC treatment) with the allogeneicdonor eASC were studied. HLA II is an indication of in-vivo immunerecognition of the donor eASC. Percentage expression of the HLA-IImarker is provided in FIG. 3. It was demonstrated that patients in theresponder group had a significant down-regulation of HLA-II expression.At baseline in the non-responder group mean HLA-II expression was 22.93with a standard deviation of +/−9.5 in PBMC and a mean of 23.77 withstandard deviation +/−9.91 for co-cultured PBMC+ASCS. In the respondergroup mean HLA-II expression was 24.35+/−12.51 in PBMC, whichsurprisingly decreased to 17.73 with a standard deviation of +/−9.71 inthe co-cultured PBMC+ASCS.

Furthermore, this down-regulation was also observed at day 15 indicatingthat the HLA-II marker may be used in determining clinical response bothprior to and during the early stages of treatment.

TABLE 1 Treatment CD4 CD8 HLA-II Patient Response Assay Assay Assay 1Non-responders ✓ ✓ ✓ 2 ✓ ✓ ✓ 3 X x ✓ 4 ✓ ✓ ✓ 5 ✓ ✓ ✓ 6 X x ✓ 7 ✓ ✓ ✓ 8 ✓✓ ✓ 9 ✓ ✓ ✓ 10 X x ✓ 11 ✓ ✓ ✓ 12 ✓ ✓ ✓ 13 ✓ ✓ ✓ 14 ✓ ✓ ✓ 15 ✓ ✓ ✓ 16Responders X x ✓ 17 ✓ ✓ ✓ 18 ✓ ✓ ✓ 19 ✓ ✓ ✓ 20 ✓ ✓ ✓ 21 X x ✓ 22 ✓ ✓ ✓23 ✓ ✓ ✓ 24 ✓ ✓ ✓

1. A method for predicting clinical response to the administration of apharmaceutical composition comprising of stem cells, stromal cells,regulatory T-cells, fibroblasts and combinations in a patient sufferingfrom tissue damage, an ischemic, an inflammatory and/or an immunedisorder thereof by evaluating one or more lymphocytes markers.
 2. Amethod for treating a human subject having tissue damage, an ischemic,an inflammatory and/or an immune disorder with a pharmaceuticalcomposition comprising of stem cells (preferably mesenchymal stemcells), stromal cells, regulatory T-cells, fibroblasts and combinationsthereof comprising i) determining whether the patient is a responder ora non-responder to said pharmaceutical composition by evaluating alymphocyte marker in a blood sample obtained from said human subject andii) administering said pharmaceutical composition only if the humansubject is determined to be a responder.
 3. A method according to claim1 or 2 wherein said lymphocyte marker is selected from the groupcomprising CD4+ lymphocyte level, CD8+ lymphocyte level, lymphocyteHLA-II level and combinations thereof.
 4. A method according to any ofclaims 1 to 3 wherein a subject having a CD4+ level equal to or lessthan a value in the range of 35% to 55% of the total T-lymphocytes isclassified as a responder.
 5. A method according to any of claims 1 to 3wherein a subject having a CD8+ level equal to or greater than a valuein the range of 45% to 65% of the total T-lymphocytes is classified as aresponder.
 6. A method according to any of claims 1 to 3 wherein asubject having a CD4:CD8+ ratio equal to or lower than 1.5 is classifiedas a responder.
 7. A method according to any of claims 1 to 3 wherein asubject having a reduction in lymphocyte HLA-II level after contactthereof with allogeneic mesenchymal stem cells is classified as aresponder.
 8. A method according to any of claims 1 to 7 wherein thestem cells are mesenchymal stem cells.
 9. A method according to any ofclaims 1 to 8 wherein the stem cells are multipotent stromal or stromalstem cells.
 10. A method according to claim 8 or 9 wherein themesenchymal stem cells are adipose tissue derived mesenchymal stemcells.
 11. A method according to either of claims 1 to 10 wherein thestem cells are allogeneic stem cells.
 12. A pharmaceutical compositioncomprising of stem cells, stromal cells, regulatory T-cells, fibroblastsand combinations thereof for use in the treatment, modulation,prophylaxis, and/or amelioration of one or more symptoms associated withtissue damage, an ischemic, an inflammatory and/or an immune disorder ina human subject wherein said human subject has a CD4+ level equal to orless than a value in the range of 35% to 55% of T-lymphocytes.
 13. Apharmaceutical composition comprising of stem cells, stromal cells,regulatory T-cells, fibroblasts and combinations thereof for use in thetreatment, modulation, prophylaxis, and/or amelioration of one or moresymptoms associated with tissue damage, an ischemic, an inflammatoryand/or an immune disorder in a human subject wherein said human subjecthas a CD8+ level equal to or greater than a value in the range of 45% to65% of T-lymphocytes.
 14. A pharmaceutical composition comprising ofstem cells, stromal cells, regulatory T-cells, fibroblasts andcombinations thereof for use in the treatment, modulation, prophylaxis,and/or amelioration of one or more symptoms associated with tissuedamage, an ischemic, an inflammatory and/or an immune disorder in ahuman subject wherein said human subject has a CD4:CD8 ratio equal to orlower than 1.5.
 15. A pharmaceutical composition comprising of stemcells, stromal cells, regulatory T-cells, fibroblasts and combinationsthereof for use in the treatment, modulation, prophylaxis, and/oramelioration of one or more symptoms associated with tissue damage, anischemic, an inflammatory and/or an immune disorders in a human subjectwherein said human subject has a reduction in lymphocyte HLA-II levelafter contact thereof with allogeneic mesenchymal stem cells.
 16. Use ofstem cells, stromal cells, regulatory T-cells, fibroblasts andcombinations thereof for the preparation of a pharmaceutical compositionfor the treatment, modulation, prophylaxis, and/or amelioration of oneor more symptoms associated with tissue damage, an ischemic, aninflammatory and/or an immune disorder in a human subject wherein saidhuman subject has a CD4+ level equal to or less than a value in therange of 35% to 55% of T-lymphocytes.
 17. Use of stem cells, stromalcells, regulatory T-cells, fibroblasts and combinations thereof for thepreparation of a pharmaceutical composition for the treatment,modulation, prophylaxis, and/or amelioration of one or more symptomsassociated with tissue damage, an ischemic, an inflammatory and/or animmune disorder in a human subject wherein said human subject has a CD8+level equal to or greater than a value in the range of 45% to 65% ofT-lymphocytes.
 18. Use of stem cells, stromal cells, regulatory T-cells,fibroblasts and combinations thereof for the preparation of apharmaceutical composition for the treatment, modulation, prophylaxis,and/or amelioration of one or more symptoms associated with tissuedamage, an ischemic, an inflammatory and/or an immune disorder in ahuman subject wherein said human subject has a CD4:CD8 ratio equal to orlower than 1.5.
 19. Use of stem cells, stromal cells, regulatoryT-cells, fibroblasts and combinations thereof for the preparation of apharmaceutical composition for the treatment, modulation, prophylaxis,and/or amelioration of one or more symptoms associated with tissuedamage, ischemic, inflammatory and/or an immune disorders in a humansubject wherein said human subject has a reduction in lymphocyte HLA-IIlevel after contact thereof with allogeneic mesenchymal stem cells.